UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

Current Report

Pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (date of earliest event reported): May 23, 2016

Balchem Corporation
(Exact name of registrant as specified in its charter)

Maryland
1-13648
13-257-8432
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)

New Hampton, NY 10958
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (845) 326-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Item 8.01. Other Events

On May 23, 2016, Balchem Corporation issued a press release regarding the establishment of a Reference Dietary Intake (RDI) of 550mg of choline by the U.S. Food and Drug Administration (FDA).  A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

99.1 Press Release issued by Balchem Corporation on May 23, 2016.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
BALCHEM CORPORATION
   
 
By:/s/ Matthew D. Houston
 
Matthew D. Houston, General Counsel and
Secretary
   
Dated: May 23, 2016
  
 
EXHIBIT INDEX

Exhibit Number Description

99.1 Press Release issued by Balchem Corporation on May 23, 2016